Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair.

Beam Therapeutics has set its sights on an accelerated approval of its base editing therapy for the severe form of alpha-1 ...

Beam Therapeutics BEAM announced positive updated safety and efficacy data from a phase I/II study evaluating its pipeline ...

Beam Therapeutics (NASDAQ:BEAM) executives and clinical collaborators presented updated top-line data from the company’s ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) gained about 8% on Wednesday after the company released updated results from ...

Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins ...

Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in early-to-mid-stage development for treating certain hematology and genetic diseases. The ...